中文 | English
 
李诗良



李诗良,博士

副研究员,硕导

  

电话:021-64250213

邮箱:shiliangli@ecust.edu.cn

地址:实验18516

  

个人简介:

2007-2016年,在华东理工大学药学院药物科学系学习,师从李洪林教授,20166月获医学博士学位;20167-201810月在华东理工大学药学院从事博士后研究,合作导师为徐玉芳教授。201811月以特聘副研究员的身份留校,主要从事基于结合热/动力学的药物设计、药物设计及靶标预测新方法的开发及应用研究。采用多策略药物设计方法,结合化学合成和药理筛选,针对癌症、糖尿病及自身免疫性疾病相关的重要靶标(RSK2, EGFR, DHODH, DPP4等)进行了系统性的药物设计研究,发现了一批骨架新颖的活性化合物和先导结构,在课题组长带领下,现已有三个候选药物(1.1类)进入临床前研究(已技术转让给制药公司3个)。截止目前,已在J. Med. Chem., J. Chem. Inf. Model.等专业期刊上发表SCI论文26篇,其中第一作者论文9篇,通讯作者论文3篇;申请发明专利4项,其中中国授权1项,国际PCT专利两项。获得国家自然科学基金青年项目、第60批博士后面上等及2018年度上海市“科技创新行动计划”青年科技英才扬帆计划共3项资助;此外,还作为主要研究人员参与国家重点研发计划课题一项,国家新药创制重大专项一项。

 

代表性论文

1.     Shiliang Li#, Chun Qin#, Shichao Cui#, Hongling Xu, Fangshu Wu, Jiawei Wang, Mingbo Su, Xiaoyu Fang, Dan Li, Qian Jiao, Ming Zhang, Chunmei Xia, Lili Zhu, Rui Wang, Jia Li, Hualiang Jiang, Zhenjiang Zhao*, Jingya Li*, Honglin Li*. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J. Med. Chem.  2019. 62(5): 2348-2361.

2.     Shiliang Li#, Hongling Xu#, Shichao Cui#, Fangshu Wu#, Youli Zhang, Mingbo Su, Yinghui Gong, Shaobing Qiu, Qian Jiao, Chun Qin, Jiwei Shan, Ming Zhang, Jiawei Wang, Qiao Yin, Minghao Xu, Xiaofeng Liu, Rui Wang, Lili Zhu, Jia Li, Yufang Xu, Hualiang Jiang, Zhenjiang Zhao*, Jingya Li*, Honglin Li*. Discovery and Rational Design of Natural Product-Derived 2-phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. J. Med. Chem. 2016, 59 (14): 6772-6790.

3.     Shiliang Li#, Guoqin Luan#, Xiaoli Ren#, Wenlin Song, Liuxin Xu, Minghao Xu, Junsheng Zhu, Dong Dong, Yanyan Diao, Xiaofeng Liu, Lili Zhu, Rui Wang, Zhenjiang Zhao*, Yufang Xu*, Honglin Li*. Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity. Sci. Rep., 2015. 5: 14836.

4.     Shiliang Li#, Yi Zhou#, Weiqiang Lu#, Ye Zhong, Jin Huang, Zhenjiang Zhao, Yufang Xu, Xiaofeng Liu*, Honglin Li*. Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-based Virtual Screening with the Inhibitor-constrained Refined Homology Model. J. Chem. Inf. Model., 2011. 51(11): 2939-2947.

5.     Jiajia Meng#Shiliang Li#, Xiaofeng Liu, Mingyue Zheng, Honglin Li*. RD-Metabolizer: an Integrated and Reaction Types Extensive Approach to Predict Metabolic Sites and Metabolites of Drug-like Molecules. Chem. Cent. J.2017. 11: 65.




网页发布时间: 2018-11-07